Puma Biotechnology Stock Earnings Reports

Key points for investors:

- Q1 2026 revenue: Total revenue $44.8M; product revenue (primarily NERLYNX) $42.0M, down from $59.9M in Q4 2025. Q1 product revenue was impacted by an estimated $7.9M inventory drawdown at specialty pharmacies/distributors. Ex-factory bottle sales were 2,328 in Q1 (≈ -29% QoQ, ≈ flat YoY). New prescriptions rose ~25% QoQ while total prescriptions fell ~4% QoQ.

- Commercial highlights: Continued emphasis on dose escalation (≈78% start at reduced dose), increased HCP engagement (call activity +44% YoY), growth in specialty distributor channel (notably GPOs). NERLYNX launched in Thailand (extended adjuvant setting).

- Financial outlook and liquidity: Management raised 2026 net NERLYNX product revenue guidance to $202M–$206M (up from prior $194M–$198M). Full-year 2026 royalty guidance $20M–$23M. Gross-to-net expected ~26.5%–27.5% for 2026. Full-year net income guidance increased to $16M–$19M. Company ended March 31, 2026 with ~$101.5M cash and, after an April payment, is debt-free.

- R&D and trials: Puma presented interim Phase II (ALISCA) data for alisertib in small cell lung cancer (ALISCA-Lung1) and HER2-negative ER+ breast cancer (ALISCA-Breast1). Signals indicate greater activity in biomarker-defined (c-Myc–high) populations and apparent enrichment in ESR1-mutant / PIK3CA–wild-type subgroups in breast cancer. Safety appears manageable with mandated G-CSF prophylaxis in lung trial; neutropenia rates improved vs. historical comparators. Dose escalation to 70 mg BID (lung) planned in H2 2026; combination lung study with paclitaxel (ALISCA-Lung2) targeted to start H2 2026. Breast trial enrollment will be expanded to focus on biomarker-enriched cohorts in H2 2026 with updated data expected then.

- Investment implications: Early biomarker-driven efficacy signals could enable a more focused registrational strategy (particularly in ER+ breast where ESR1/PIK3CA testing is common). Management highlights disciplined cost control and intent to maintain positive net income; R&D spend is increasing to support ALISCA programs (R&D expected +34%–37% YoY in 2026). Key near-term catalysts: additional ALISCA interim updates (H2 2026/early 2027), enrollment/biomarker enrichment readouts, and execution against raised 2026 commercial guidance.